Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chuanpu Hu

Showing results (51-60 of 56) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 56 results.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|April 16, 2016
Towards patient stratification and treatment in the autoimmune disease lupus erythematosus using a systems pharmacology approachM Leire Ruiz-Cerdá, Itziar Irurzun-Arana, Ignacio González-Garcia, et al.
Journal of Clinical Pharmacology|July 21, 2009
Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha human monoclonal antibody, in patients with psoriatic arthritisZhenhua Xu, Thuy Vu, Howard Lee, et al.
Alzheimer'S & Dementia (New York, N. Y.)|June 2, 2018
Alzheimer's disease progression model using disability assessment for dementia scores from bapineuzumab trialsSteven X Xu, Mahesh N Samtani, Alberto Russu, et al.
Alzheimer'S & Dementia (New York, N. Y.)|June 2, 2018
Alzheimer's disease assessment scale-cognitive 11-item progression model in mild-to-moderate Alzheimer's disease trials of bapineuzumabMahesh N Samtani, Steven X Xu, Alberto Russu, et al.
Journal of Pharmacokinetics and Pharmacodynamics|December 20, 2024
Novel endpoints based on tumor size ratio to support early clinical decision-making in oncology drug-developmentShubhadeep Chakraborty, Kshitij Aggarwal, Marzana Chowdhury, et al.
Journal of Alzheimer'S Disease : JAD|May 11, 2016
Biomarker Exposure-Response Analysis in Mild-To-Moderate Alzheimer's Disease Trials of BapineuzumabAlberto Russu, Mahesh N Samtani, Steven Xu, et al.
Pageof 6

Showing results (51-60 of 56) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 56 results.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|April 16, 2016
Towards patient stratification and treatment in the autoimmune disease lupus erythematosus using a systems pharmacology approachM Leire Ruiz-Cerdá, Itziar Irurzun-Arana, Ignacio González-Garcia, et al.
Journal of Clinical Pharmacology|July 21, 2009
Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha human monoclonal antibody, in patients with psoriatic arthritisZhenhua Xu, Thuy Vu, Howard Lee, et al.
Alzheimer'S & Dementia (New York, N. Y.)|June 2, 2018
Alzheimer's disease progression model using disability assessment for dementia scores from bapineuzumab trialsSteven X Xu, Mahesh N Samtani, Alberto Russu, et al.
Alzheimer'S & Dementia (New York, N. Y.)|June 2, 2018
Alzheimer's disease assessment scale-cognitive 11-item progression model in mild-to-moderate Alzheimer's disease trials of bapineuzumabMahesh N Samtani, Steven X Xu, Alberto Russu, et al.
Journal of Pharmacokinetics and Pharmacodynamics|December 20, 2024
Novel endpoints based on tumor size ratio to support early clinical decision-making in oncology drug-developmentShubhadeep Chakraborty, Kshitij Aggarwal, Marzana Chowdhury, et al.
Journal of Alzheimer'S Disease : JAD|May 11, 2016
Biomarker Exposure-Response Analysis in Mild-To-Moderate Alzheimer's Disease Trials of BapineuzumabAlberto Russu, Mahesh N Samtani, Steven Xu, et al.
Pageof 6